HST GLOBAL, INC. Inactive Instrument
HST Global, Inc. Stock Other OTC
Equities
HSTC
US40432E2028
Biotechnology & Medical Research
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 3.19M |
|---|---|---|---|---|---|
| Net income 2022 | - | Net income 2023 | - | EV / Sales 2022 | - |
| Net Debt 2022 | 75.89K | Net Debt 2023 | 96.79K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.34
x | P/E ratio 2023 |
-21.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.71% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ron Howell
CEO | Chief Executive Officer | 75 | 08-05-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ron Howell
CEO | Chief Executive Officer | 75 | 08-05-07 |
HST Global, Inc. is an integrated health and wellness biotechnology company. The Company is focused on developing and /or acquiring a network of wellness centers worldwide that is primarily focused on the homeopathic and alternative treatment of late-stage cancer. The Company intends to acquire innovative products for the treatment of life-threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late-stage cancer and/or life-threatening diseases. The Company has not generated any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| +4.09% | 43.84B | |
| +9.45% | 41.68B | |
| +45.77% | 41.25B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +1.28% | 12.29B | |
| +29.70% | 12.29B | |
| +7.78% | 11.15B |
